Hyperliquid Strategies Inc Common Stock (NASDAQ:PURR) — Market Cap & Net Worth
Market Cap & Net Worth: Hyperliquid Strategies Inc Common Stock (PURR)
Hyperliquid Strategies Inc Common Stock (NASDAQ:PURR) has a market capitalization of $548.75 Million ($548.75 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12044 globally and #2843 in its home market, demonstrating a 5.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hyperliquid Strategies Inc Common Stock's stock price $6.27 by its total outstanding shares 127025563 (127.03 Million).
Hyperliquid Strategies Inc Common Stock Market Cap History: 2025 to 2026
Hyperliquid Strategies Inc Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $452.21 Million to $796.45 Million (0.00% CAGR).
Hyperliquid Strategies Inc Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hyperliquid Strategies Inc Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PURR by Market Capitalization
Companies near Hyperliquid Strategies Inc Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Hyperliquid Strategies Inc Common Stock by market ranking:
- Morgan Stanley (SA:MSBR34): Ranked #51 globally with a market cap of $293.89 Billion USD ( R$1.50 Trillion BRL).
- Morgan Stanley (NYSE:MS): Ranked #63 globally with a market cap of $272.01 Billion USD.
- Goldman Sachs Group Inc (NYSE:GS): Ranked #78 globally with a market cap of $236.20 Billion USD.
- Charles Schwab Corp (NYSE:SCHW): Ranked #135 globally with a market cap of $162.66 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #51 | Morgan Stanley | SA:MSBR34 | $293.89 Billion | R$188.48 |
| #63 | Morgan Stanley | NYSE:MS | $272.01 Billion | $190.17 |
| #78 | Goldman Sachs Group Inc | NYSE:GS | $236.20 Billion | $923.71 |
| #135 | Charles Schwab Corp | NYSE:SCHW | $162.66 Billion | $91.54 |
Hyperliquid Strategies Inc Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Hyperliquid Strategies Inc Common Stock's market cap moved from $452.21 Million to $ 796.45 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $796.45 Million | +76.12% |
| 2025 | $452.21 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Hyperliquid Strategies Inc Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $548.75 Million USD |
| MoneyControl | $548.75 Million USD |
| MarketWatch | $548.75 Million USD |
| marketcap.company | $548.75 Million USD |
| Reuters | $548.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hyperliquid Strategies Inc Common Stock
Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York.